{"schema_version":"secwatch.filing_event.v1","accession":"0000914121-23-000003","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.192590+00:00","generated_at":"2026-06-20T19:21:02.292602+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AngioDynamics Q2 FY2023 sales $85.4M (+9.1% YoY); GAAP loss $0.21/sh, adj EPS $0.01; reaffirms guidance","bullets":["Net sales $85.4M, up 9.1% YoY; Med Tech +29.7% to $24.5M, Med Device +2.6% to $60.9M.","GAAP net loss $0.21 per share; adjusted EPS $0.01 vs adjusted loss $0.02 a year ago.","Adjusted EBITDA $7.5M, up from $4.4M in prior-year quarter.","FY2023 guidance reaffirmed: net sales $342-348M, gross margin ~52.5-54.5%, adj EPS $0.01-$0.06.","Cash $29.9M, $50M in debt; Preserve prostate cancer study enrollment passed midpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0000914121-23-000003","json":"https://secwatch.observer/filing/0000914121-23-000003.json","markdown":"https://secwatch.observer/filing/0000914121-23-000003.md","text":"https://secwatch.observer/filing/0000914121-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000091412123000003/0000914121-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000091412123000003/an58427779-8ki.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:21:02.292602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41fb68e681858061ef259b0c3d08690f82ccba68","claim":"ANGIODYNAMICS INC reported the fiscal second quarter ended November 30, 2022 results: revenue $85.4 million, net income net loss of $8.5 million, EPS loss per share of $0.21.","evidence_excerpt":"Net sales for the second quarter of fiscal 2023 were $85.4 million, an increase of 9.1% compared to the prior-year quarter. Foreign currency translation did not have a significant impact on the Company ' s net sales in the quarter. Med Tech net sales were $24.5 million, a 29.7% increase from the prior-year period. Med Tech includes the Auryon peripheral atherectomy platform, the thrombus management platform and the NanoKnife irreversible electroporation platform. Growth was driven by Auryon sales during the quarter of $10.1 million, which increased 60.6%, and NanoKnife sales of $5.5 million, which increased 49.5% compared to the second quarter of fiscal 2022. NanoKnife disposable sales were $4.2 million, which increased 45.4% compared to the second quarter of fiscal 2022. Med Device net sales were $60.9 million, an increase of 2.6% compared to the prior-year period. U.S. net sales in the second quarter of fiscal 2023 were $71.6 million, an increase of 9.6% from $65.4 million a year ago","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1275187/000091412123000003/0000914121-23-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal second quarter ended November 30, 2022"},{"label":"Revenue","value":"$85.4 million"},{"label":"Net income","value":"net loss of $8.5 million"},{"label":"EPS","value":"loss per share of $0.21"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4cdf91766384fcd856c7d70160e5705d3f9d5010","claim":"ANGIODYNAMICS INC reported the six months ended November 30, 2022 results: revenue $167.0 million, net income net loss of $21.5 million, EPS loss of $0.55 per share.","evidence_excerpt":"For the six months ended November 30, 2022: Net sales were $167.0 million, an increase of 7.5%, compared to $155.3 million for the same period a year ago. Med Tech net sales were $47.3 million, a 29.7% increase from the prior year period. Med Device net sales were $119.6 million, an increase of 0.7% from the prior year period. Gross margin increased 30 basis points to 52.3% from 52.0% a year ago. The Company’s net loss was $21.5 million, or a loss of $0.55 per share, compared to a net loss of $15.3 million, or a loss of $0.39 per share, a year ago. Excluding the items shown in the non-GAAP reconciliation table, below, adjusted net loss was $2.1 million, with adjusted loss per share of $0.05, compared to adjusted net loss and adjusted loss per share of $1.7 million, and $0.04, respectively, a year ago. Adjusted EBITDA, excluding the items shown in the reconciliation table below, was $10.4 million, compared to $8.0 million for the same period a year ago.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1275187/000091412123000003/0000914121-23-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended November 30, 2022"},{"label":"Revenue","value":"$167.0 million"},{"label":"Net income","value":"net loss of $21.5 million"},{"label":"EPS","value":"loss of $0.55 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f325846453e935ab202569248a356b6a669aa69c","claim":"ANGIODYNAMICS INC reported fiscal year 2023 results: revenue $342 to $348 million, EPS adjusted earnings per share in the range of $0.01 to $0.06. Guidance reaffirmed.","evidence_excerpt":"Management is reaffirming its previously issued fiscal year 2023 guidance. Management expects net sales to be in the range of $342 to $348 million, gross margin to be approximately 52.5% to 54.5% and adjusted earnings per share in the range of $0.01 to $0.06 as it continues to invest in new product launches to drive future growth.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1275187/000091412123000003/0000914121-23-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"$342 to $348 million"},{"label":"EPS","value":"adjusted earnings per share in the range of $0.01 to $0.06"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}